Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
    • Sjögren’s Disease
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pain

FDA Approves Tremfya (Guselkumab) for Adult Patients with Psoriatic Arthritis

Natasha Yetman  |  July 15, 2020

HORSHAM, PA—The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.1,2 Tremfya is the first treatment approved for active PsA that selectively inhibits interleukin (IL)…

Filed under:Biologics/DMARDsDrug Updates Tagged with:FDA approvalguselkumabU.S. Food and Drug Administration (FDA)

A Primer on the Management of Scleroderma Emergencies

Jason Liebowitz, MD, FACR  |  July 14, 2020

Patient with autoimmune disease may experience medical emergencies. Here is an overview of recognition and management of three emergent situations for patients with scleroderma: critical digital ischemia, scleroderma renal crisis and intestinal pseudo-obstruction…

Filed under:ConditionsSystemic Sclerosis Tagged with:intestinal pseudo-obstructionischemiaScleroderma Renal Crisis

FDA Approves Canakinumab for Adult-Onset Still’s Disease

Michele B. Kaufman, PharmD, BCGP  |  July 14, 2020

Canakinumab, an interleukin (IL) 1 blocker, can now be prescribed to treat patients with active Still’s disease and adult-onset Still’s disease (AOSD)…

Filed under:ConditionsDrug UpdatesOther Rheumatic Conditions Tagged with:adult Still's DiseasecanakinumabFDAU.S. Food and Drug Administration (FDA)

Biologic Treatment Recommendations for Rheumatic Disease Patients Who Contract COVID-19

Thomas R. Collins  |  July 7, 2020

COVID-19 Global Alliance registry and other data on rheumatic disease patients with COVID-19 were presented…

Filed under:ConditionsDrug UpdatesEULAR/OtherMeeting Reports Tagged with:biologic drugsCOVID-19EULARimmunosuppressivepatient care

Caring for Pediatric Patients During a Pandemic: Q&A with Jay Mehta, MD

Mary Beth Nierengarten  |  July 6, 2020

Caring for pediatric patients during a pandemicin the age of COVID-19 requires adaptations, says Jay Mehta, MD, Children’s Hospital of Philadelphia. “The one exposure that seems to put [pediatric] patients at risk is if they are on higher doses of steroids, with some data suggesting worse outcomes. We just put out guidelines telling providers to reduce steroids in their patients to the lowest dose that can adequately control their disease.”

Filed under:Practice SupportProfessional Topics Tagged with:COVID-19Jay MehtaPediatric Rheumatology

In Memoriam … J. Timothy Harrington, MD, MACR: July 6, 1940–June 23, 2020

William Arnold, MD; Tim Bartholow, MD; Drew Johnson, MS, MBA; Joel Kremer, MD; Daniel Malone, MD; Eric D. Newman, MD; Kenneth Saag, MD; & Douglas White, MD  |  June 30, 2020

June saw the passing of a beloved colleague, mentor and friend to many in the rheumatology community when J. Timothy Harrington, MD, died of pancreatic cancer in his hometown of Madison, Wis. Dr. Harrington trained at Massachusetts General Hospital, the National Institutes of Health National Cancer Institute and UT Southwestern Medical Center, and served on…

Filed under:Professional TopicsProfiles Tagged with:Dr. J. Timothy HarringtonHarrington

Respiratory Failure More Common in COVID-19 Patients with Rheumatic Disease

Marilynn Larkin  |  June 23, 2020

NEW YORK (Reuters Health)—COVID-19-infected patients with rheumatic disease were more likely to experience respiratory failure than those without rheumatic disease, according to a retrospective study in China. “Immune dysregulation underlying rheumatic diseases may affect the disease manifestation of COVID-19,” Dr. Jixin Zhong of Huazhong University of Science and Technology, Wuhan, tells Reuters Health by email….

Filed under:Uncategorized Tagged with:coronavirusCOVID-19respiratoryRheumatic Disease

Some Rheumatic Diseases Tied to Higher Risk of Severe COVID-19

Megan Brooks  |  June 23, 2020

NEW YORK (Reuters Health)—Patients with some inflammatory rheumatic conditions are at higher risk for hospital-diagnosed COVID-19 infection compared with the general population, but it depends on the condition and therapy used to treat it, according to a study from Spain. It’s now clear that older patients and those with some common diseases are at increased…

Filed under:Conditions Tagged with:coronavirusCOVID-19Rheumatic Disease

Basilisks in Rheumatology: The Hunt for Rheumatic Mysteries Shrouded in Enigmas & Wrapped in Puzzles

Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS  |  June 23, 2020

What do rheumatology and wizardry have in common? More than you may think. Like basilisks, rheumatic diseases are often elusive and changing in presentation…

Filed under:Professional Topics

Florida Society of Rheumatology in the Spotlight

Linda Childers  |  June 18, 2020

Advocacy efforts on access and workforce issues in Florida are discussed.

Filed under:Professional Topics Tagged with:Dr. Guillermo ValenzuelaDr. Reshma KhanFlorida Society of Rheumatologystate society

  • « Previous Page
  • 1
  • …
  • 76
  • 77
  • 78
  • 79
  • 80
  • …
  • 243
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences